Women with the KRAS-variant have up to a six-fold increased risk of developing breast and ovarian cancer, as well as an increased risk of non-small cell lung cancer. New data indicates that changing estrogen levels and withdrawal increases or triggers cancer risk for women with this genetic mutation. In addition, women with the KRAS-variant appear to be at a significantly higher risk of multiple primary cancer, including multiple primary breast cancer. Knowing a woman’s KRAS-variant status is an additional piece of information to help direct decisions for screening, risk reduction and estrogen management.
The KRAS-variant has been shown to significantly predict which medicines will and will not work for cancer patients. This information can subgroup patients into responders or non-responders to therapies being used today as standard of care. Knowing a patient’s KRAS-variant status affords the opportunity to personalize treatment and ultimately get better results.
Currently, there are no biomarkers used to identify patients who may be over-sensitive to radiation therapy, which is a treatment used for over 75% of cancer patients. MiraDx is developing a panel of such biomarkers, including the KRAS-variant, as well as preparing individual patient testing to diagnose those with ATM.
Despite the dangers of the KRAS-variant mutation, few doctors have heard of it. But one researcher is trying to change that.